Skip to content

Bethea A Kleykamp

3 papers in the library · 79 citations · publishing 2013-2023

Papers

Sort Most recent Most cited

Control Conditions in Randomized Trials of Psychedelics

The Journal of Clinical Psychiatry May 4, 2023 Sandeep M. Nayak, Melissa Bradley, Bethea A Kleykamp et al. 38 citations

To systematically review control conditions of all available randomized psychedelic trials. We searched PubMed, PsycINFO, and EMBASE for randomized trials of psychedelics in humans from 1940 through May 2020 with no language restrictions. PRISMA guidelines were followed. (PROSPERO registration number: PROSPERO-CRD42020205341.). All randomized trials of psychedelics in humans from 1940 through...

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

JAMA Psychiatry 2023 Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al. 22 citations

Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Psychopharmacology March 1, 2013 Lawrence P Carter, Bethea A Kleykamp, Roland R. Griffiths et al. 19 citations

Several studies have documented impairments in memory processes as a result of ketamine administration; however, few studies have compared the profile of cognitive effects of ketamine to other drugs. The aim of this study was to compare the cognitive effects of ketamine with those of triazolam in healthy volunteers. Doses of ketamine (0.2, 0.4 mg/kg intramuscular (i.m.)), triazolam (0.2, 0.4...